

## Correction: Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency

Jayaraju Dheekollu<sup>1</sup>, Kimberly Malecka<sup>1</sup>, Andreas Wiedmer<sup>1</sup>, Henri-Jacques Delecluse<sup>2</sup>, Alan K.S. Chiang<sup>3</sup>, Dario C. Altieri<sup>1</sup>, Troy E. Messick<sup>1</sup> and Paul M. Lieberman<sup>1</sup>

<sup>1</sup>The Wistar Institute, Philadelphia, PA USA

<sup>2</sup>Deutsches Krebsforschungszentrum, Heidelberg, Germany


<sup>3</sup>Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong

### Published:


**Copyright:** Dheekollu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has been corrected:** Due to errors in image selection, Figure 5A shows an inadvertent duplicate of Donor 2 for M81. Figure 7D shows the Actin control from Donor 2 that was inadvertently duplicated from the Donor 2 Actin control shown in Figure 4 (which is the same extract and donor sample). Figure 4 is correct and unchanged. The corrected Figure 5 and Figure 7 are shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:7248–7264. <https://doi.org/10.18632/oncotarget.14540>



**Figure 5: Defective B-cell blast formation by B95-8/npEBNA1.** Bacmid-derived virus for B95-8, M81, or B95-8/npEBNA1 were assayed at 2 weeks post-infection of primary B-lymphocytes. **A.** GFP positive B-cell blasts for two independent donors were analyzed by high-throughput microscopy. **B.** The number of colonies imaged by microscopy with diameters of > 100, 50-100, or 25-100 $\mu$ M were quantified by Image J (panel B). **C.** B-cell blasts at 4 weeks post-infection were analyzed by FACS for apoptosis using propidium iodide (PI) (x-axis) and annexin V (y-axis). **D.** The percentage of live and necrotic cells assayed by FACS were quantified for two independent donors and three independent biological replicates.



**Figure 7: Low episome copy number and terminal repeat instability in LCLs with B95-8/npceBNA1.** **A.** PFGE analysis of LCLs generated with recombinant B95-8, M81, or B95-8/npceBNA1 virus. Samples are run as technical replicates for two independent donor generated LCLs. Cellular  $\alpha$ -satellite DNA is shown as loading control above each lane. **B.** Quantitation of EBV episomes relative to  $\alpha$ -satellite DNA for PFGE shown in panel A. **C.** Southern blot analysis of EBV terminal repeats after digestion with BamHI for B95-8, M81, or B95-8/npceBNA1 generated LCLs. **D.** Western blot for EAD, ZTA, EBNA1, EBNA2, and Actin for B95-8, M81, or B95-8/npceBNA1 generated LCLs.